In Fig 1A, we could indeed show that increasing concentrations of vemurafenib inhibited downstream ERK1/2 phosphorylation (T202/Y204) in primary BRAF-mutant melanoma cells and to a lesser degree in BRAF-WT melanoma cells after 1 h. Here, MAPK3 is linked to melanoma.